AACR 2026 saw thousands gathered in San Diego, California, where major progress in cancer research was revealed.

There has been a swing towards in vivo CAR-T therapies lately, as big pharmas sign acquisition deals and new therapies hit ...

Delve into the field of PARP inhibitors, a class that has gained traction in ovarian, breast, and prostate cancers.

Discover the emerging class of degrader-antibody conjugates – a modality that is drawing increasing interest from biotech ...

Researchers have used modified CRISPR to silence the extra chromosome 21 in Down syndrome cells, showing promising ...

Single-cell analysis is reshaping drug discovery, but interpretation remains slow. AI single cell approaches may close the ...

Discover some of the new atopic dermatitis treatments in clinical development that could overcome existing challenges in the ...

Vision loss remains one of the leading causes of disability worldwide, with millions affected by inherited retinal diseases, age-related macular degeneration, and diabetic eye disease. While existing ...

Gilead Sciences is entering a pivotal moment in its evolution. Long defined by its dominance in antivirals, particularly for HIV, the company now faces a strategic challenge: the need to meaningfully ...

Chimeric antigen receptor (CAR)-T cell therapies have gone down in history as a major breakthrough in cancer treatment. Although more advanced cell therapies attempt to overcome the limitations of CAR ...